Cited 0 times in
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, MJ | - |
dc.contributor.author | Park, BB | - |
dc.contributor.author | Ahn, JS | - |
dc.contributor.author | Kim, SW | - |
dc.contributor.author | Kim, HT | - |
dc.contributor.author | Lee, JS | - |
dc.contributor.author | Kang, JH | - |
dc.contributor.author | Cho, JY | - |
dc.contributor.author | Song, HS | - |
dc.contributor.author | Park, SH | - |
dc.contributor.author | Sohn, CH | - |
dc.contributor.author | Shin, SW | - |
dc.contributor.author | Choi, JH | - |
dc.contributor.author | Ki, CS | - |
dc.contributor.author | Park, CK | - |
dc.contributor.author | Holmes, AJ | - |
dc.contributor.author | Jänne, PA | - |
dc.contributor.author | Park, K | - |
dc.date.accessioned | 2010-12-23T01:37:34Z | - |
dc.date.available | 2010-12-23T01:37:34Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/772 | - |
dc.description.abstract | PURPOSE: This study investigated possible molecular predictors of outcome in Korean patients with advanced non-small cell lung cancer treated with erlotinib.
EXPERIMENTAL DESIGN: One hundred and twenty patients received erlotinib and were followed prospectively. Ninety-two tissue samples were analyzed for epidermal growth factor receptor (EGFR) gene mutations (exons 18, 19, and 21), 88 for EGFR gene amplification by real-time PCR, and 75 for EGFR protein expression by immunohistochemistry. RESULTS: The overall tumor response rate was 24.2% (complete response, 4; partial response, 25) with 56.7% of disease control rate. With a median follow-up of 23.6 months, the median time to progression (TTP) was 2.7 months and the median overall survival was 12.9 months. EGFR gene mutations were found in 26.1% (24 of 92), EGFR gene amplification in 40.9% (36 of 88), and EGFR protein expression in 72% (54 of 75). There was a strong association between EGFR gene mutations and gene amplification (gamma = 0.241). Patients with EGFR gene mutations or gene amplification showed both better response rate (58.3% versus 16.2%, P < 0.001; 41.7% versus 17.3%, P = 0.012) and TTP (8.6 versus 2.5 months, P = 0.003; 5.8 versus 1.8 months, P < 0.001) and overall survival (not reached versus 10.8 months, P = 0.023; not reached versus 10.1 months, P = 0.033). By multivariate analysis, EGFR gene mutation was the only significant molecular predictor for TTP (hazard ratio, 0.47; 95% confidence interval, 0.25-0.89). CONCLUSIONS: Our findings indicate that EGFR gene mutation is a more predictive marker for improved TTP than EGFR gene amplification in erlotinib-treated Korean non-small cell lung cancer patients. Prospective studies from diverse ethnic backgrounds are required to determine the exact role of these molecular markers. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung | - |
dc.subject.MESH | DNA Mutational Analysis | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Ethnic Groups | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genes, erbB-1 | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Quinazolines | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Markers, Biological | - |
dc.title | Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? | - |
dc.type | Article | - |
dc.identifier.pmid | 18559606 | - |
dc.identifier.url | http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18559606 | - |
dc.contributor.affiliatedAuthor | 최, 진혁 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-07-4608 | - |
dc.citation.title | Clinical cancer research | - |
dc.citation.volume | 14 | - |
dc.citation.number | 12 | - |
dc.citation.date | 2008 | - |
dc.citation.startPage | 3860 | - |
dc.citation.endPage | 3866 | - |
dc.identifier.bibliographicCitation | Clinical cancer research, 14(12). : 3860-3866, 2008 | - |
dc.relation.journalid | J010780432 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.